Wednesday, October 14, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· June 30, 2026

Kneat Files Management Information Circular in Connection with the Previously Announced Thoma Bravo Transaction

View original at globenewswire.com
Kneat Files Management Information Circular in Connection with the Previously Announced Thoma Bravo Transaction Proposed Transaction Provides Significant, Immediate, and Certain Value to Shareholders Proposed Transaction Result of Comprehensive, Multi-Month Strategic Review Process Led by an Independent and Qualified S…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Our Board members and executives have all agreed to support the Proposed Transaction, believing that it represents the best outcome for the Company.

    60% confidence
  • The purchase price of C$6.50 per share exceeds Kneat's 52-week high closing price and represents a 40% premium to the May 8, 2026 closing price, and 57%, 61%, and 54% premiums to the 30-, 60- and 90-day VWAP as of May 8, 2026.

    60% confidence
  • The Board unanimously determined that the Proposed Transaction is in the best interests of shareholders and reflects an attractive value considering Kneat's risk-adjusted standalone opportunity.

    60% confidence
  • The Proposed Transaction values Kneat at an enterprise value of C$622 million, approximately 7.2x NTM revenue and approximately 9.3x LTM revenue, significantly higher than peers and precedent transactions.

    60% confidence
  • ARR growth has decelerated significantly from 51% in Q1 2025 to 20% in Q1 2026, and growth is increasingly dependent on uncertain large customer expansion.

    60% confidence
  • Competitive pressure is intensifying as established enterprise software vendors advance their own validation capabilities and actively solicit Kneat's customers, threatening its market share.

    60% confidence
  • The Kneat Board of Directors urges shareholders to vote FOR the Proposed Transaction today, believing it is in the best interests of the Company and its shareholders.

    60% confidence
  • Prior to the public announcement of the strategic review, Kneat's stock price had declined approximately 35% from its all-time high, sector valuation multiples had contracted, and analysts had reduced revenue and EBITDA estimates.

    60% confidence
  • The Special Committee reached out to 36 financial sponsors and 10 strategic buyers, of which 34 sponsors and 2 strategic buyers signed NDAs; management engaged 18 interested parties, 12 of which submitted indicative offers; negotiations resulted in a material increase to Thoma Bravo's bid.

    60% confidence
  • Kneat's customer base remains heavily concentrated, with the top 10 customers accounting for approximately 50% of revenue, exposing the Company to significant revenue volatility.

    60% confidence
  • The Board believes the proposed transaction with Thoma Bravo is in the best interests of the Company and maximizes value for shareholders.

    60% confidence
  • Ongoing investment in R&D, sales, and G&A mean Kneat is likely to remain unprofitable for the foreseeable future, limiting financial flexibility.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com